Black Diamond Therapeutics Inc.

09/23/2024 | Press release | Distributed by Public on 09/23/2024 05:08

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti tumor Activity of BDTX 1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.